… on these results we propose that our deepening knowledge of how LRRK2 dysregulation of PKA results in Parkinson’s-like symptoms could provide strong rationale for new therapeutic … we may be able to pursue this pathway as a therapeutic target.   Next Steps for Development: Although it is a …

… as the cell’s degradation and recycling center. Lysosomes stop working properly in Parkinson’s disease and accumulate … In this study, we will further optimize and identify a lead compound to advance into preclinical safety studies. These …

… New York City marathon for The Michael J. Fox Foundation to raise money for Parkinson's disease research. Three … raised $90,000 for Parkinson's research. Learn more on how you can become a Team Fox Athlete . Laxmi Wordham …

… December 29, 2022: Community advocacy has been critical to pushing forward The National Plan to End Parkinson’s Act … before the end of the year. For more information about how this bill will work its way through Congress,  check out …

… A new formulation of amantadine to better treat levodopa-induced dyskinesia is entering the … reduction in LID at 12 weeks in patients receiving ADS-5102 compared with placebo, as assessed by the Unified Dyskinesia … met its primary endpoint.[...] Results from the study showed an improvement in activities of daily living (ADLs) in …

… ineffectiveness of these treatment strategies may be due to a lack of understanding of the biological processes … normally curb the experience of pain.  Our new results show that mice that experiences changes in the brainstem … techniques from multiple scientific disciplines to show how cells in the brainstem and spinal cord that are …